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Conclusions Comprehensive CYP2D6 genotyping has 
a good predictive value for CYP2D6 activity. Common 
variants in CYP2C9, CYP2C19, CYP2D6, and CYP2B6 did 
not have a significant impact on the rFt in this cohort of 
patients with BC.
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Abbreviations
aS  activity score
BC  Breast cancer
DFS  Disease-free survival
DM  Dextromethorphan
DX  Dextrorphan
er  estrogen receptor
eDta  ethylenediaminetetraacetic acid
eM  extensive metabolizer
HPlC  High pressure liquid chromatography
IM  Intermediate metabolizer
PM  Poor metabolizer
Pr  Progesterone receptor
PCr  Polymerase chain reaction
rFt  relapse-free time
StD  Standard deviation
UM  Ultrafast metabolizer
4-OH-tamoxifen  4-Hydroxytamoxifen
Introduction
Breast cancer (BC) is one of the most frequent can-
cers in the Western world. tamoxifen, a selective estro-
gen receptor modulator (SerM), is widely used as an 
Abstract 
Background tamoxifen is frequently used for the treat-
ment of hormone receptor positive breast cancer (BC). 
Mainly CYP2D6 is responsible for the transformation to 
therapeutically active metabolites, but CYP2C19, CYP2C9 
and CYP2B6 also are involved. We investigated the impact 
of polymorphisms within the genes encoding these CYP 
enzymes on the relapse-free time (rFt) in patients with BC.
Methods ninety-nine patients with hormone receptor posi-
tive BC, who had undergone adjuvant tamoxifen therapy, 
were genotyped for seventeen common variants within the 
genes encoding CYP2D6, CYP2C9, CYP2C19 and CYP2B6 
using taqMan and PCr-rFlP technology. Kaplan–Meier 
and Cox regression analyses were performed to elucidate the 
impact of genetic variants on rFt. Furthermore, CYP2D6 
metabolic activity was determined in a subset of 50 patients 
by assessing dextromethorphan/dextrorphan urinary excre-
tion ratios. CYP2D6 activity was compared to the CYP2D6 
allelic combinations to evaluate the predictive value of the 
CYP2D6 genotyping results on phenotype.
Results although a trend toward longer rFts in carri-
ers of CYP2D6 allele combinations encoding for exten-
sive and ultrafast metabolizer phenotypes was observed, 
none of the investigated genetic variants had a statistically 
significant impact on rFt. the combined analysis of five 
major CYP2D6 variants was useful for the discrimination 
between poor and non-poor metabolizers.
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efficient therapeutic option in the treatment and relapse 
prevention of estrogen receptor (er)-positive BC [12]. 
tamoxifen is transformed predominantly by the drug-
metabolizing enzymes CYP3a4 and CYP2D6 into the 
therapeutically more efficient drug metabolites 4-hydrox-
ytamoxifen (4-OH-tamoxifen) and endoxifen. By binding 
to the er α (erα) tamoxifen and its metabolites modu-
late, the estrogen-induced transcription of erα target 
genes. the metabolites 4-OH-tamoxifen and endoxifen 
show up to 100 times higher affinity to the erα than 
the parental compound [7]. as a result, the efficacy of 
tamoxifen strongly depends on its appropriate bioactiva-
tion by cytochrome P450 enzymes. CYP2D6 is highly 
polymorphic and shows a high interindividual variability 
in its activity. Currently, there are more than 100 genetic 
variants described for CYP2D6 [21]. Several genetic 
variants are known to cause an impaired enzyme activ-
ity (CYP2D6*10, *41) or to even induce a total loss of 
enzyme function (e.g., CYP2D6*4, *5, *6). Further-
more, gene duplications or multiplications of CYP2D6 
that occur in 2–3 % of white individuals may lead to an 
exceptionally fast metabolism of CYP2D6 substrates. 
genetic polymorphisms of CYP2D6 have been repeat-
edly associated with a changed therapeutic outcome in 
patients with BC treated with tamoxifen. Several stud-
ies could demonstrate that genetic variants causing an 
impaired CYP2D6 enzyme activity or even a loss of 
CYP2D6 function are associated with a shorter relapse-
free time (rFt) upon tamoxifen therapy [10, 20]. Other 
studies, however, showed conflicting results. especially 
in studies where the efficacy of tamoxifen in relation to 
the CYP2D6 metabolizer status was tested in an adjuvant 
setting, no clear relationship between CYP2D6 status and 
therapeutic outcome was observed [16, 18]. the latter 
studies are, however, controversial in the literature, due to 
the facts that Dna was isolated from tumor tissues and 
not from blood and that Hardy–Weinberg equilibria were 
partly not reached for several CYP2D6 genetic variants 
[14, 23]. Other enzymes involved in tamoxifen metabo-
lism comprise CYP2C9, CYP2C19 and CYP2B6 [13]. 
these three enzymes are also involved in the formation 
of 4-OH-tamoxifen and endoxifen, but their contribution 
may depend on actual tamoxifen concentrations and on 
CYP2D6 activity.
In this study, we studied the impact of genetic variants 
in the genes encoding the drug-metabolizing enzymes 
CYP2C9, CYP2C19, CYP2B6 and CYP2D6 on the rFt 
in patients with BC treated with tamoxifen in an adjuvant 
setting. We chose to investigate genetic variants that have 
been demonstrated to have a significant impact on the met-
abolic efficacy of the enzymes in focus in order to evaluate 
to which extent these polymorphisms might be suitable to 
predict the therapeutic outcome with tamoxifen.
Patients and methods
Patients
ninety-nine patients were included in this study. Patients 
were of Caucasian origin, diagnosed with early-stage er-
positive BC and treated with adjuvant tamoxifen. Patients 
were recruited at the Breast Center, Zurich, Switzerland 
between July 2009 and December 2012. tumors were dem-
onstrated to be er positive in all patients and 91 % had a 
>20 % er expression on the surface. the majority of cases 
also exhibited Pr. Patients were treated with tamoxifen alone 
or sequentially with aromatase inhibitors (aIs) as the pri-
mary treatment choice. In case of a chemotherapeutic treat-
ment (75.8 %), regimens comprised the combinations FeC 
(5-fluorouracil, epirubicin and cyclophosphamide), FeC-
tXt (5-fluorouracil, epirubicin, cyclophosphamide and doc-
etaxel) or eC-taX (epirubicin, cyclophosphamide and pacli-
taxel). Data of primary BC diagnosis and disease recurrence 
were confirmed from the patients’ pathological and medical 
records. the study was approved by the local ethical com-
mittee of Zurich, and written informed consent was obtained. 
the demographic and disease-associated characteristics of all 
patients included in the study are shown in table 1.
genotyping
From all patients, a whole blood sample was collected 
in ethylenediaminetetraacetic acid vials. genomic Dna 
was extracted using the QIaamp Dna Mini Kit (Qiagen, 
Hilden, germany) according to the manufacturer’s rec-
ommendations. extracted Dna was used to genotype all 
patients for 17 genetic variants within the genes encoding 
cytochrome P450 enzymes involved in the metabolism 
of tamoxifen. the genotyping comprised the allelic vari-
ants CYP2C9*2 and *3, CYP2C19*2, *3, *4, *6 and *17, 
CYP2B6*6, *7 and *16, CYP2D6*3, *4, *5, *6, *10 and 
*41 as well as analysis of CYP2D6 gene duplications/
multiplications. the majority of variants were determined 
using taqMan SnP assay technology (agilent technolo-
gies, Santa Clara, Ca, USa). the variant CYP2D6*41 was 
analyzed using a conventional nested PCr approach fol-
lowed by digestion of the PCr product with the restriction 
enzyme BsepMI. the forward primer used in the second 
PCr carried an artificial mutation in the area of the 3′ end, 
thereby creating a functional restriction site for BsepMI in 
interplay with the wild type form at the CYP2D6*41 locus. 
the determination of CYP2D6 duplications/multiplications 
was performed as described previously [24].
genotypes of CYP2D6 were assigned to the expected 
corresponding metabolizer phenotypes according to the 
evaluation system by gaedigk et al. [8]. the genotype/phe-
notype assignments are summarized in table 2.
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CYP2D6 phenotyping and CYP2D6 metabolizer type 
assignment
Phenotypes predicted on the basis of CYP2D6 genotypes 
were compared to the CYP2D6 phenotypes measured in a 
subset of patients with BC. Phenotypic data were obtained 
by high pressure liquid chromatography (HPlC) according 
to the methods described by abdel-rahman et al. [1] and 
Blake et al. [3]. HPlC-based phenotype was determined 
as follows: 6 h after the intake of 25 mg dextromethorphan 
(DM), a prototypical CYP2D6 substrate, the concentra-
tions of methyl-dextrorphan (MD) and its O-demethylated 
metabolite dextrorphan (DX) were determined in the urine 
of 50 patients by reversed-phase HPlC with fluorescence 
detection. For this purpose, 1.25 ml of each urine sample 
was deglucuronidated by adding 500 μl phosphate buffer 
and 25 μl glucuronidase. the samples were incubated 
at 50 °C, cooled down, and subsequently centrifuged and 
included in the further analysis. the DM/DX ratios were 
calculated using the peak height concentrations of DM 
Table 1  Demographic information and disease characteristics of patients treated with tamoxifen for the treatment of breast carcinoma (% in 
parentheses unless stated otherwise)
a
 Fisher’s exact tests or chi-square tests were performed
b
 the Mann–Whitney U test was performed
all (n = 99) no relapse (n = 84) relapse (n = 15) p valuea
age (years, median, range) 48 (28–77) 48 (28–73) 50 (37–77) ns
Stage
 I–IIa 65 (65.7) 57 (67.9) 8 (53.3) ns
 IIb–IIIc 34 (34.3) 27 (32.1) 7 (46.7)
er > 20 % 90 (90.9) 81 (96.4) 9 (60.0) <0.001
Pr presence 84 (84.8) 75 (89.3) 9 (60.0) ns
Her-2 positive 22 (22.2) 21 (25.0) 1 (6.7) ns
grade
 1 10 (10.1) 9 (10.7) 1 (6.7)
 2 46 (46.5) 40 (47.6) 6 (40.0) ns
 3 43 (43.4) 35 (41.7) 8 (53.3)
Observational period (months (min–max)) 47.8 (12–130) 51.6 (12–130) 26.5 (12–72) <0.001b
tamoxifen intake (months (min–max)) 30.4 (12–77) 32.3 (12–77) 19.9 (12–50) 0.003b
aI intake (months (min–max)) 10.3 (0–64) 9.8 (0–50) 12.9 (0–64) nsb
Premenopause (%) 47 (47.5) 40 (47.6) 7 (46.7) ns
Chemotherapy (%) 75 (75.8) 63 (75.0) 12 (80.0) ns
Table 2  Prediction of CYP2D6 enzyme activity based on CYP2D6 genotyping results and the assignment of activity scores (aS) according to 
gaedigk et al. [8, 9]
a
 aS assignment to alleles: *3, *4, *5, *6 (non-functional), aS 0; *10, *41, aS 0.5 (reduced function); *1, aS 1 (wild type allele); duplication/
multiplication, aS 2 (increased function)
b
 Only observed genotypes are listed
c
 the chi-square test was applied
Designation aS value assigned to the 
allelic combinationsa
genotypesb all
n = 98 (%)
no relapse
n = 83 (%)
relapse
n = 15 (%)
p valuec
Poor metabolizer (PM) 0 *4/*4, *6/*6 6 (6.7) 5 (6.0) 1 (6.7) ns
Intermediate metabolizer (IM) 0.5 *3/*10, *4/*10, *6/*10
*4/*41, *6/*41
33 (33.7) 27 (32.5) 6 (40.0)
1 *1/*3, *1/*4, *1/*5, *1/*6, 
*10/*10, *10/*41, *41/*41
9 (9.2) 8 (9.6) 1 (6.7)
1.5 *1/*10, *1/*41 20 (20.4) 18 (21.7) 2 (13.3)
extensive metabolizer (eM) 2 *1/*1 25 (25.5) 22 (26.5) 3 (20.0)
Ultrarapid metabolizer (UM) >2 Duplications or multiplica-
tions of functional alleles
5 (5.1) 3 (3.6) 2 (13.3)
1184 Cancer Chemother Pharmacol (2014) 73:1181–1188
1 3
and DX, determined by HPlC. Patients were considered 
as CYP2D6 phenotypic poor metabolizer (PM), when 
exhibiting a DM/DX excretion ratio of >0.3, as described 
previously [4, 25]. Furthermore, patients were evaluated 
as CYP2D6 phenotypic intermediate metabolizers (IM), 
extensive metabolizer (eM) or UM, when showing DM/DX 
metabolic ratios of 0.03–0.3, 0.0003–(<0.03) and <0.0003, 
respectively.
Statistical analysis
the chi-square test and the Fisher’s exact test were used to 
compare categorical variables, such as the dichotomized 
response measure in relation to the abundance of differ-
ent genetic variants (e.g., genotype frequencies) or any 
pathological molecular markers within the patient groups. 
Continuous data (e.g., age or duration of tamoxifen/aI 
intake) are given as median ± StD or mean plus time 
range and were compared using the Mann–Whitney U test. 
the Kruskal–Wallis test was performed to compare the 
observed DM/DX ratios in the predicted CYP2D6 pheno-
type groups.
the rFt was determined in patients who were taking 
tamoxifen for at least 12 months. the rFt was defined as 
the time interval in months between the time point of BC 
diagnosis and the occurrence of the first relapse of disease. 
a relapse was defined as the occurrence of an event such 
as either metastatic disease, local or distant recurrence of 
the tumor or a new invasive primary BC. the rFt was 
estimated using the Kaplan–Meier method and statistically 
analyzed using the log-rank test. a two-sided p value of 
<0.05 was considered statistically significant. the impact 
of any putative confounders on rFt, such as tumor stage, 
chemotherapy, menopausal or er status was tested per-
forming a Cox regression analysis. the program SPSS 
(version 21, SPSS Inc., Chicago, Il, USa) was used for 
statistical analysis.
Results
ninety-nine patients were genotyped for 17 different poly-
morphisms in the genes encoding the drug-metabolizing 
enzymes CYP2C9, CYP2C19, CYP2D6 and CYP2B6 
using leukocytic Dna. In case of CYP2D6, seven different 
genetic variants were determined, including gene duplica-
tions/multiplications and the most important variants (*3, 
*4, *5, *6, *10, *41) responsible for an impaired enzyme 
activity or the expression of null alleles. With the exception 
of the mutation CYP2C19*6, all variants were in Hardy–
Weinberg-equilibrium. the variant CYP2C19*6 appeared 
only once in homozygous form in the cohort and was there-
fore calculated to be in Hardy–Weinberg-disequilibrium.
Fifteen patients developed a relapse of BC within the 
observational period. table 1 demonstrates and compares 
the demographic and disease characteristics of the individ-
uals showing a relapse with the patient group that stayed 
disease-free during the time of observation. In general, 
no significant differences were observed when compar-
ing both groups with regard to age, disease stage, grade 
or menopausal status. a relapse was significantly less fre-
quently observed in patients with >20 % er expression 
(p < 0.001, chi-square test). the observational period and, 
consequently, the average time of tamoxifen intake was sig-
nificantly longer in the relapse-free group (p < 0.001 and 
p = 0.003, respectively).
eighty-six patients were successfully genotyped for 
CYP2D6 duplications/multiplications. In view of the 
obtained allele combinations for CYP2D6, an assignment 
of an activity score (aS) was possible in ninety-eight 
patients ([9], table 2). as demonstrated in table 2, no sig-
nificant differences were detected in the overall frequencies 
of predicted CYP2D6 phenotypes in relation to the relapse 
status. additionally, genotype-based predicted CYP2D6 
phenotypes were correlated with the experimentally con-
firmed phenotype (urinary DM/DX metabolic ratio) in a 
subgroup of 50 patients, where both the genotypic and 
phenotypic information was available. as demonstrated in 
Fig. 1, the metabolic DM/DX ratios differed significantly 
between the predicted CYP2D6 phenotypes (p = 0.001, 
Kruskal–Wallis test). the prediction of phenotypes based 
on genotyping results was especially well reproducible for 
the discrimination between poor and non-PM (table 3). a 
sensitive discrimination between intermediate, extensive 
and ultrafast metabolizers was, however, only possible to a 
limited extent (Fig. 1; table 3).
all 99 patients were included into the analysis inves-
tigating, to which extent the genotypes of CYP2C9, 
CYP2C19, CYP2D6 and CYP2B6 influence the relapse 
time in patients with BC treated with tamoxifen. In sev-
eral sub analyses, the er status, the menopausal state and 
a concomitant chemotherapeutic treatment were considered 
additional putative risk factors and were also taken into 
consideration. In the case of er status, it was assumed that 
an expression degree of >20 % would be an important pre-
requisite for an efficient therapy approach with antiestro-
gens, such as tamoxifen. the average duration of tamoxifen 
intake was 30 months (range of 12–77 months) and aIs 
10 months (range of 0–64 months). the median follow-
up time of patients was 46 months. to analyze the influ-
ence of genetic variants detected in CYP2C9, CYP2C19, 
CYP2B6 and CYP2D6 genes on the BC–rFt, the follow-
ing approach was adopted. First, the frequencies of variant 
carriers (heterozygous plus homozygous individuals) were 
compared in the relapse and relapse-free groups before 
(table 4) and after a logistic regression analysis stratifying 
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for er density, menopausal state, disease grade and stage 
and an additional chemotherapeutic treatment. Second, the 
rFts were analyzed in relation to the investigated geno-
types using the Kaplan–Maier method without and with 
stratification for er and menopausal status (Cox regres-
sion analysis). no significant associations were observed 
between CYP2C9, CYP2C19 and CYP2B6 genotypes and 
the risk for a BC relapse before or after stratification for the 
different putative confounders. the er state appeared to be 
an independent risk factor for the development of a disease 
relapse: 6 of 9 patients with an er expression below or 
equal to 20 % had a relapse in comparison to 9 of 90 with 
an er expression above 20 % (p < 0.001). as demonstrated 
in Fig. 2, a trend toward a lower relapse rate was observed 
for individuals carrying allelic combinations that induce 
an eM or UM genotype of CYP2D6 (p = 0.19). this trend 
was repeatedly observed, when stratifying for different risk 
confounders.
Discussion
Several studies could demonstrate that interindividual dif-
ferences in the activity of CYP2D6 may affect the thera-
peutic outcome in patients with BC receiving tamoxifen in 
an adjuvant setting [19, 20]. Besides CYP2D6, other drug-
metabolizing enzymes play a role in the in vivo transforma-
tion of tamoxifen, but were, in this context, rarely inves-
tigated. therefore, our aim was to study to which extent 
genetic polymorphisms in CYP2D6, CYP2C9, CYP2C19 
and CYP2B6 either alone or in interplay with each other 
influence the relapse risk under treatment with tamoxifen in 
a cohort of Caucasian patients with BC.
although not significant, we could show in concord-
ance with previous studies [19, 20] that genotypes associ-
ated with normal or increased CYP2D6 activity lead to a 
favorable treatment outcome under tamoxifen, when tak-
ing the re-occurrence of BC as a primary endpoint. this 
trend toward lower relapse rates can be explained by the 
increased production of the potent metabolites 4-OH-
tamoxifen and endoxifen. the variant CYP2C19*17 has 
been associated with a fast metabolizer phenotype of 
CYP2C19 due to an increased expression of CYP2C19 [2, 
22]. CYP2C19*17 may, thus, lead to an augmented produc-
tion of 4-OH-tamoxifen, which may improve the treatment 
outcome as reported by Schroth et al. [19]. In our study, 
however, we did not observe an effect of CYP2C19*17 on 
treatment outcome, neither when analyzing the impact of 
the *17 variant on the relapse rate alone nor in combination 
with fast metabolizer genotypes of CYP2D6.
Different genotypes of CYP2C9, CYP2C19 or CYP2B6 
did not significantly alter the risk for a relapse of BC under 
treatment with tamoxifen, which underlines the stronger 
impact of CYP2D6 on tamoxifen pharmacokinetics. Of 
note, we used Dna from peripheral blood mononuclear 
cells (PBMCs) for our analysis, which more accurately 
reflects the Dna sequence of CYP genes in the liver, 
whereas Dna obtained from tumor samples may harbor 
Fig. 1  CYP2D6 phenotypes were predicted on the basis of CYP2D6 
activity scores, as calculated from CYP2D6 genotyping results. Pre-
dicted CYP2D6 phenotypes were correlated with measured CYP2D6 
phenotypes, determined on the basis of urinary DM/DX ratios. Fifty 
patients were included, where both genotype and phenotype data 
were available. the plot represents median values with data ranges. 
the Kruskal–Wallis test detected significant differences in DM/DX 
ratios between the different aS score groups (p = 0.001)
Table 3  Concordance of 
predicted and measured 
CYP2D6 phenotypes in a subset 
of patients with BC
genotype-based predicted Patients (n = 50) Concordance Observed phenotype 
(based on DM/DX ratio)
CYP2D6 phenotype n (%) Predicted/observed Median range
PM 3 (6) 3/4 1.803 1.490–5.337
IM 36 (72) 36/32 0.097 0.004–0.433
eM 8 (16) 8/13 0.016 0.000–0.090
UM 3 (6) 3/1 0.021 0.016–0.130
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additional cancer-induced mutations, as has been recently 
discussed [17].
although several meta-analyses demonstrated that 
patients with CYP2D6 eM genotypes/phenotypes 
as compared to slow metabolizer geno- and pheno-
types have a longer disease-free survival, the overall 
survival appeared not to be significantly influenced by 
the CYP2D6 metabolizer state in tamoxifen-treated BC 
patients. Furthermore, these studies provided inconclu-
sive results with regard to potential treatment guidelines 
for tamoxifen based on CYP2D6 genotyping results. 
[11, 15, 26].
Table 4  genotype frequencies of CYP2C9, CYP2C19, CYP2B6 and CYP2D6 before and after stratification for disease behavior in 99 patients 
with BC
a
 n denotes the absolute number of individuals carrying the respective genotype
b
 In each subgroup, the abundance of CYP2D6 gene duplications/multiplications is compared (left column not abundant, right column abundant)
gene allele genotype, na (%),  
all patients
genotype, n (%),  
relapse-free group
genotype, n (%),  
relapse group
p value (variant 
vs. non-variant 
carrier)
wt het hom wt het hom wt het hom
CYP2C9 *2 76 (76.8) 22 (22.2) 1 (1.0) 65 (77.4) 18 (21.4) 1 (1.2) 11 (73.3) 4 (26.7) 0 (0.0) ns
*3 85 (85.9) 13 (13.1) 1 (1.0) 70 (83.3) 13 (15.5) 1 (1.2) 15 (100) 0 (0.0) 1 (1.0) ns
CYP2C19 *2 72 (72.7) 22 (22.2) 5 (5.1) 60 (71.4) 20 (23.8) 4 (4.8) 12 (80.0) 2 (13.3) 1 (6.7) ns
*3 99 (100.0) 0 (0.0) 0 (0.0) 84 (100.0) 0 (0.0) 0 (0.0) 15 (100.0) 0 (0.0) 0 (0.0) ns
*4 98 (99.0) 1 (1.0) 0 (0.0) 83 (98.8) 1 (1.2) 0 (0.0) 15 (100.0) 0 (0.0) 0 (0.0) ns
*6 98 (99.0) 0 (0.0) 1 (1.0) 83 (98.8) 0 (0.0) 1 (1.2) 15 (100.0) 0 (0.0) 0 (0.0) ns
*17 67 (67.7) 28 (28.3) 4 (4.0) 57 (67.9) 23 (27.4) 4 (4.8) 10 (66.7) 5 (33.3) 0 (0.0) ns
CYP2B6 *6 54 (54.5) 40 (40.4) 5 (5.1) 46 (54.8) 34 (40.5) 4 (4.8) 8 (53.3) 6 (40.0) 1 (6.7) ns
*7 80 (82.5) 17 (17.5) 0 (0.0) 68 (82.9) 14 (17.1) 0 (0.0) 80 (82.5) 17 (17.5) 0 (0.0) ns
*16 98 (99.0) 1 (1.0) 0 (0.0) 83 (98.8) 1 (1.2) 0 (0.0) 15 (100.0) 0 (0.0) 0 (0.0) ns
CYP2D6 *3 96 (98.0) 2 (2.0) 0 (0.0) 81 (97.6) 2 (2.4) 0 (0.0) 15 (100.0) 0 (0.0) 0 (0.0) ns
*4 60 (61.2) 34 (34.7) 4 (4.1) 52 (62.7) 28 (33.7) 3 (3.6) 8 (53.3) 6 (40.0) 1 (6.7) ns
*5 97 (98.0) 2 (2.0) 0 (0.0) 83 (98.8) 1 (1.2) 0 (0.0) 14 (93.3) 1 (6.7) 0 (0.0) ns
*6 93 (94.9) 4 (4.1) 1 (1.0) 78 (94.0) 4 (4.8) 1 (1.2) 15 (100.0) 0 (0.0) 0 (0.0) ns
*10 52 (53.1) 39 (39.8) 7 (7.1) 44 (53.0) 34 (41.0) 5 (6.0) 8 (53.3) 5 (33.3) 2 (13.3) ns
*41 75 (79.8) 18 (19.1) 1 (1.1) 64 (80.0) 15 (18.8) 1 (1.3) 11 (78.6) 3 (21.4) 0 (0.0) ns
Dupl./Multipl.b 77 (89.5) 9 (10.5) 66 (90.4) 7 (9.6) 11 (84.6) 2 (15.4) ns
Fig. 2  Kaplan–Meier analyses determining and comparing the 
rFt in months in individuals carrying CYP2D6 slow metabolizer 
(PMs plus IMs) and fast metabolizer genotypes (eMs plus UMs) 
(a), CYP2C19 wild type and CYP2C19*17 heterozygous (het) or 
homozygous (hom) (b), or CYP2B6 wild type and CYP2B6*6 hete-
rozygous (het) or homozygous (hom) (c). although not significant, a 
trend toward a more favorable disease outcome was observed for car-
riers of genotypes coding for CYP2D6 fast metabolizer phenotypes 
(p = 0.19). the comparisons in case of CYP2C19 and CYP2B6 poly-
morphisms were not significant (p ns)
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Instead of assigning four metabolizer phenotypes to gen-
otypes, we tested the application of the CYP2D6 genotyp-
ing evaluation system of gaedigk et al. [9], which weighs 
the impact of different CYP2D6 genotypes on CYP2D6 
enzyme activity by assigning aS to the allelic combina-
tions. By correlating predicted to observed CYP2D6 phe-
notypes, we could demonstrate that the aS system, if based 
on comprehensive CYP2D6 genotyping results, appears to 
be a useful approach to discriminate between slow and eM. 
Phenotypic poor and IM were especially well predicted. 
a finer discrimination especially between intermediate, 
extensive and ultrafast metabolizers is, however, not reli-
ably possible based on this system. Since not all possible 
genetic variations in CYP2D6 were investigated in our 
study, misclassification may also arise from the assignment 
of the *1 allele to individuals who harbor a rare, activity-
lowering CYP2D6 mutation. additionally, CYP2D6 pheno-
typing by using urinary dextromethorphan-based metabo-
lite ratios may not be the optimal phenotyping tool, because 
small activity differences cannot be reliably detected [5, 6], 
which in turn, may also lead to misclassifications.
Besides an estrogen receptor expression below 20 %, no 
other factor like demographics, menopausal state or chemo-
therapy regimen used were identified as a risk for a relapse.
Our study includes a limited number of individuals and 
was performed in a retrospective manner. Both aspects 
could potentially weaken the associations between geno-
types and therapeutic outcome with tamoxifen especially in 
cases, where a polymorphism might have a weak impact on 
the BC recurrence risk. the data reported here should be 
validated in future by the performance of prospective stud-
ies assessing the impact of CYP2D6 variants on the thera-
peutic outcome of BC in large cohorts of tamoxifen-treated 
BC patients.
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